FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Accelerates Landmark Approvals to Under Two Months

FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Accelerates Landmark Approvals to Under Two Months

First unveiled in June 2025 under FDA Commissioner Dr. Marty Makary, the Commissioner’s National Priority Voucher (CNPV) Pilot Program has emerged as one of the most powerful and highly accelerated regulatory pathways in modern drug development. Designed to compress typical FDA review timelines from 10 to 12 months down to just 1 to 2 months (or even weeks), the CNPV program awards non-transferable priority vouchers¹ to investigational products that address key national priorities. These priorities include critical unmet medical needs, domestic manufacturing resilience, and healthcare affordability.

Mechanics and Focus of the CNPV Program

Unlike traditional Priority Review Vouchers (PRVs)—which are restricted to tropical or rare pediatric diseases and are highly tradeable on the secondary market—the CNPV program has a broader, more flexible scope. Key features include:

• Broad Criteria: Eligibility extends to therapies addressing major national health priorities (e.g., cancer, addiction, infectious diseases) and products that strengthen the domestic pharmaceutical supply chain or lower prices for American patients.
• Lightning-Fast Timelines: Complete applications utilizing a CNPV are targeted for review decisions within 1 to 2 months.
• Enhanced Communication: Sponsors receive intensive, early communication and rolling feedback from the FDA during clinical development to de-risk submissions.

Notable Approvals and Milestones

By late August 2026, the CNPV pilot program has backed several highly consequential regulatory clearances:

1. Revolution Medicines' Rasonque (daraxonrasib) — August 26, 2026: Approved for advanced pancreatic ductal adenocarcinoma just weeks after filing, coming 6.5 months ahead of its traditional user fee deadline.
2. Vertex's Casgevy Pediatric Expansion — July 1, 2026: Granted approval for children as young as 2 with sickle cell disease just 53 days after filing, representing the 8th approval under the CNPV program.
3. Zenocutuzumab (Bizengri) — May 8, 2026: Approved for adults with rare NRG1 fusion-positive cholangiocarcinoma (bile duct cancer), marking the 7th approval under the pilot program.
4. Augmentin XR — December 15, 2025: Approved as part of an effort to bolster domestic production capacity and counter active shortages of critical antibiotics.

The First Major Rejection: Disc Medicine's Bitopertin

The program's speed does not guarantee automatic clearance. In February 2026, the FDA issued its first Complete Response Letter (CRL) under the new program, rejecting Disc Medicine’s bitopertin for erythropoietic protoporphyria (EPP) despite its early CNPV designation. This demonstrated that the agency continues to hold voucher-backed submissions to rigorous safety and efficacy standards. Disc Medicine subsequently met with the FDA in June 2026, securing a "clear path" to a potential resubmission following further clinical data.

Political and Regulatory Backlash

The rapid rollout and broad scope of the CNPV program have drawn intense scrutiny from lawmakers and legal scholars. Critics argue that the program bypasses traditional congressional oversight and risks eroding scientific evidence standards by relying on smaller, less rigorous trials.

• In late 2025, Representative Frank Pallone and Senator Bernie Sanders launched a formal investigation into the program's legal authority.
• Opponents, such as Representative Jake Auchincloss, have publicly criticized the initiative, stating:

  "The FDA is replacing safety & efficacy with fear & favor. The CNPV is the tip of the spear. Unless Congress stops it, the commissioner will pursue more illegal, unethical, and unwise efforts."

Despite this resistance, the program continues to reshape clinical trial operations and regulatory strategies across the biopharmaceutical industry, serving as a key driver of ultra-fast drug approvals in 2026.